Pfizer to begin clinical trial to assess the safety and immunological response of their Omicron-specific vaccine


Posted on 25 January 2022


For Illustration Purpose Only.

Pfizer and BioNTech announced on January 25 that enrollment for a clinical trial to assess the safety and immunological response of their Omicron-specific COVID-19 vaccine in individuals aged 55 and below has begun. Albert Bourla, the CEO of Pfizer, had stated that the pharmaceutical firm could be ready to file for regulatory approval of the shots by March. While recent data revealed that boosters against the original COVID-19 strain continued to protect against severe outcomes with Omicron, the organization was operating cautiously, according to Kathrin Jansen, the company's head of vaccine research. The original vaccine's protection against mild and moderate COVID-19 appeared to fade quickly against Omicron, according to Ugur Sahin, CEO of BioNTech. A total of 1,420 persons between the ages of 18 and 55 will participate in the study. The study did not include anyone over the age of 55, according to a Pfizer spokesman, because the purpose of the study was to assess the immunological response of participants dosed rather than to estimate vaccination efficacy. The trial is being conducted in the United States and South Africa, with the first dose being administered in North Carolina.


Key Points


  • Pfizer and BioNTech announced on January 25 that enrollment for a clinical trial to assess the safety and immunological response of their Omicron-specific COVID-19 vaccine in individuals aged 55 and below has begun.

  • The trial is being conducted in the United States and South Africa, with the first dose being administered in North Carolina.


Follow Us On Google Newsstand: Click Here